Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …

Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the
Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well …

Breast cancers are complex ecosystems of malignant cells and the tumour
microenvironment. The composition of these tumour ecosystems and interactions within …

Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …

Microarray-based gene expression profiling has had a major effect on our understanding of
breast cancer. Breast cancer is now perceived as a heterogeneous group of different …

Simple Summary Triple-negative breast cancer (TNBC) is a highly aggressive subtype of
breast cancer that cannot be treated with endocrine therapy and Her2-targeted therapy …

BACKGROUND: Taxanes are established in the treatment of metastatic breast cancer (MBC)
and early breast cancer (EBC) as potent chemotherapy agents. However, their therapeutic …

Simple Summary Triple Negative Breast Cancer represents a cancer type with an unmet
clinical need. This type of breast cancer presents the worse clinical outcome due to its …

Introduction Although human epidermal growth factor receptor 2 (HER2) positive or estrogen
receptor (ER) positive breast cancers are treated with clinically validated anti-HER2 or anti …

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype,
characterized by extensive intratumoral heterogeneity, high metastasis, and …